Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data

Executive Summary

Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron
Advertisement

Related Content

Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges
Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%
Advertisement
UsernamePublicRestriction

Register

PS043985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel